It is not yet FDA-approved and remains in Phase 3 clinical trials as of early 2026
Based at the University of Lausanne in Switzerland, Thorens had a long-standing interest in insulin resistance and diabetes from both an academic and clinical perspective
Individuals beginning semaglutide, liraglutide, or tirzepatide should receive counseling about potential skin reactions related to GLP-1 therapy
Pharmacoeconomics 33 , 673689 (2015)
After eating a meal, your intestines release a hormone called GLP-1, which signals your pancreas to release more insulin
Bedogni G, Grugni G, Tringali G, Marazzi N, Sartorio A